Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2018 · 38 citations · 27 references
MedicineMolecular BiologyNeurologyDementiaMolecular DiagnosticsNeurodegenerationAlzheimer DiseaseBiomarkers Of NeurodegenerationDementia BiomarkersDementia DiagnosisNeurodegenerative DiseasesNeurodegenerative DisordersAlzheimer Disease DementiaAmyloid Beta PeptidesAmyloid Beta PlaquesDisease-specific BiomarkersHigh-molecular-weight KininogenHigh-sensitivity AssaysNeuritic PlaquesWestern Blot Analysis
INTRODUCTION: Accumulation of β-amyloid is a pathological hallmark of Alzheimer's disease (AD). β-Amyloid activates the plasma contact system leading to kallikrein-mediated cleavage of intact high-molecular-weight kininogen (HKi) to cleaved high-molecular-weight kininogen (HKc). Increased HKi cleavage is observed in plasma of AD patients and mouse models by Western blot. For potential diagnostic purposes, a more quantitative method that can measure HKc levels in plasma with high sensitivity and specificity is needed. METHODS: HKi/c, HKi, and HKc monoclonal antibodies were screened from hybridomas using direct ELISA with a fluorescent substrate. RESULTS: We generated monoclonal antibodies recognizing HKi or HKc specifically and developed sandwich ELISAs that can quantitatively detect HKi and HKc levels in human. These new assays show that decreased HKi and increased HKc levels in AD plasma correlate with dementia and neuritic plaque scores. DISCUSSION: High levels of plasma HKc could be used as an innovative biomarker for AD.
27
Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 86.9K citations
Older Adults' Reasons for Using Technology while Aging in Place
Sebastiaan Theodorus Michaël Peek, Katrien Luijkx, M. D. Rijnaard et al. · Gerontology · 2015 · 19.7K citations · Full text
The Clinical Dementia Rating (CDR)
John C. Morris · Neurology · 1993 · 10K citations
Medicine, Neurology, Psychiatry +12